ArticleGenes & cancer2012
The Roles of MDM2 and MDMX Phosphorylation in Stress Signaling to p53.
Article in Genes & cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- The Enigmatic Tumor Suppressor p53 Biomolecule: Its Role and Prognostic and Predictive Values in Cancer Therapy and Precision Medicine.Biomolecules · 2026Review
- Hyperfunction of post-synaptic density protein 95 promotes seizure response in early-stage aβ pathology.EMBO reports · 2024Article
- Mechanistic analysis of Tanshinone IIA's regulation of the ATM/GADD45/ORC signaling pathway to reduce myocardial ischemia-reperfusion injury.Frontiers in pharmacology · 2024Article
- Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death.International journal of molecular sciences · 2022Review
- MAPPINGS, a tool for network analysis of large phospho-signalling datasets: application to host erythrocyte response toCurrent research in microbial sciences · 2022Article
- The MDM2/MDMX/p53 axis in the adaptive stress response.Translational cancer research · 2020Review
- Peli1 Modulates the Subcellular Localization and Activity of Mdmx.Cancer research · 2018Article
- MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Inhibition of Mdmx (Mdm4)Oncotarget · 2018Article
- Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53.Oncotarget · 2017Article
- The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2).Oncotarget · 2017Article
- AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.Journal of molecular cell biology · 2017Article
- Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.Journal of neurosurgery · 2017Article
- MDMX under stress: the MDMX-MDM2 complex as stress signals hub.Translational cancer research · 2016Article
- The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.Cold Spring Harbor perspectives in medicine · 2016Review
- The cis conformation of proline leads to weaker binding of a p53 peptide to MDM2 compared to trans.Archives of biochemistry and biophysics · 2015Article
- Genetic Variations in the TP53 Pathway in Native Americans Strongly Suggest Adaptation to the High Altitudes of the Andes.PloS one · 2015Article
- E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.Cell death and differentiation · 2014Article
- Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.PloS one · 2014Article
- Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry.Genes & development · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The p53 tumor suppressor is highly responsive to different physiological stresses such as abnormal cell proliferation, nutrient deprivation, and DNA damage. Distinct signaling mechanisms have evolved to activate p53, which in turn modulate numerous pathways to enhance fitness and survival of the organism. Elucidating the molecular mechanisms of these signaling events is critical for understanding tumor suppression by p53 and development of novel therapeutics. Studies in the past decade have established that MDM2 and MDMX are important targets of signaling input from different pathways. Here, we focus our discussion on MDM2 and MDMX phosphorylation, which is important for p53 activation by DNA damage. Investigations in this area have generated new insight into the inner workings of MDM2 and MDMX and underscore the importance of allosteric communication between different domains in achieving an efficient response to phosphorylation. It is likely that MDM2 and MDMX regulation by phosphorylation will share mechanistic similarities to other signaling hub molecules. Phosphorylation-independent p53 activators such as ARF and ribosomal proteins ultimately achieve the same outcome as phosphorylation, suggesting that they may induce similar changes in the structure and function of MDM2 and MDMX through protein-protein interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.